SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) by Nadal, Ernest et al.
Vol.:(0123456789) 
Clinical and Translational Oncology 
https://doi.org/10.1007/s12094-020-02532-2
CLINICAL GUIDES IN ONCOLOGY
SEOM clinical guidelines for the treatment of malignant pleural 
mesothelioma (2020)
E. Nadal1  · J. Bosch‑Barrera2 · S. Cedrés3 · J. Coves4 · R. García‑Campelo5 · M. Guirado6 · R. López‑Castro7 · 
A. L. Ortega8 · D. Vicente9 · J. de Castro‑Carpeño10
Received: 20 November 2020 / Accepted: 21 November 2020 
© The Author(s) 2021
Abstract
Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos expo-
sure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction 
in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary 
tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard 
of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or 
gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immu-
notherapy demonstrated promising survival benefit and will probably be incorporated in the future.
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Introduction
Mesothelioma is an uncommon but aggressive and highly 
lethal malignant tumor arising from the serous membranes, 
being malignant pleural mesothelioma (MPM) the most 
common entity. Median age of MPM patients is 70 years, 
with increasing incidence with age and a male:female ratio 
of 3:1.
The most frequent cause of MPM is asbestos exposure 
mainly through occupational or para-occupational activities 
(e.g. cohabitants with exposed industry workers). All the 
asbestos forms are considered class 1 carcinogenic agents 
by the International Agency for Research on Cancer (IARC). 
According to the World Health Organization (WHO), about 
125 million people worldwide are exposed to asbestos at 
their workplaces, and every year more than 107,000 work-
ers die from asbestos-related diseases [1]. In this regard, the 
WHO recommends establishing registries of people with 
past and/or current exposures to asbestos and organizing 
medical surveillance of exposed workers.
Although asbestos were banned by the European Union in 
2005, due to the long latency period (usually 20–50 years) 
among asbestos exposure and MPM diagnosis, the incidence 
of MPM will peak in Western Europe during the next years. 
Given this broad interval, banning of manufacture, import or 
industrial use of asbestos will show benefits in the long term. 
In addition, environmental exposure is still a major issue 
and a proportion of deaths might be attributed to asbestos 
exposure in homes. A replacement plan of asbestos does 
not exist yet in most European countries. In Spain, asbestos 
were banned in 2002, but MPM-related deaths will not start 
to decline in the next decade, despite a discreet lowering 
in tendency of male mortality from 2001 to 2005, with an 
expected actual rate of 264 deaths/year [2].
Methods
Spanish Society of Medical Oncology (SEOM) and Span-
ish Lung Cancer Group (GECP) defined a panel of medical 
oncologists to conduct a literature search including systematic 
reviews, clinical trials, prospective and retrospective obser-
vational studies. The Infectious Diseases Society of America 
grading system was used to assign levels of evidence and 
grades of recommendation.




Pathological report should include histological subtype [IA].
Literature review Tissue specimen should confirm the pres-
ence of invasion and cytologic samples are not recommended. 
The 2015 WHO histological classification includes three main 
subtypes of MPM, epithelioid, sarcomatoid and biphasic, with 
prognostic importance [3]. A proposal for updating the histo-
logic classification of MPM was conducted by EURACAN/
IASLC, which includes more histological subtypes of MPM 
and further information as architectural patterns, grading and 
prognostic [4]. Immunohistochemical markers are useful for 
the diagnosis of MPM and for distinguishing among MPM 
subtypes from other malignancies but have limited sensitiv-
ity and specificity in sarcomatoid subtypes. Epithelioid MPM 
stains positive to calretinine, cytokeratin 5/6 and WT1 and 
is negative for CEA, EPCAM, Claudin 4 and TTF1. Loss of 
BAP1 expression and CDKN2A/p16 deletion may allow dis-
crimination of MPM from benign pleural lesions. PD-L1 and 
VISTA were not validated in MPM for its clinical use.
Genomic testing and next‑generation sequencing 
in mesothelioma
Recommendation
Studies based on large-scale genomic analysis have identi-
fied molecular subtypes and genetic alterations that may be 
actionable in the future, but genomic studies are not recom-
mended in routine clinical practice [IIIB]. A proportion of 
MPM patients carry germline mutations in cancer suscepti-
bility genes, especially those with young age and family his-
tory of cancer supporting genetic testing for selected MPM 
patients [IIIA].
Literature review MPM are dominated by the inactivation 
of tumor suppressor genes (BAP1, CDKN2A, NF2, TP53, 
LATS2 and SETD2) and generally have low tumor mutation 
burden. Although most genomic alterations in MPM are 
typically considered undruggable, the downstream signal-
ing pathways activated by these mutations, may could be 
potential therapeutic targets in the future. Germline muta-
tions has been reported in 12% of patients with MPM, but 
in higher proportion for MPM with early onset or family 
history [5]. BRCA1-associated protein (BAP1) and genes 
involved in DNA repair are the most recurrent genes.
Clinical staging in pleural mesothelioma
Recommendation
Chest computed tomography (CT) scan with intravenous 
contrast should be performed as initial evaluation in patients 
with suspected MPM [IIB]. Tumor staging will be estab-
lished according to the 8th Edition of AJCC/UICC TNM 
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staging system (Tables 1 and 2). Clinical stage along with 
other factors (patient fitness, comorbidities, tumor histology) 
will be crucial to define the level of intervention (curative 
or palliative intent) in each patient. In patients suitable for 
surgery, mediastinal biopsy by mediastinoscopy or endo-
bronchial ultrasound (EBUS) are indicated [IIB].
Literature review The clinical manifestations of MPM are 
not specific and consist of chest pain, dyspnea, fever, exces-
sive sweating and weight loss. Chest radiography might 
show pleural effusion and/or thickening. Chest CT scan 
with intravenous contrast is indicated as initial evaluation 
in patients with suspected MPM. Positron emission tomog-
raphy (PET)–CT can be helpful to assess pleural lesions 
and to assess the presence of distant metastases should be 
considered in patients considered for surgery and prior to 
talc pleurodesis. Functional magnetic resonance imaging 
Table 1  Definitions of TNM according to the 8th edition of MPM Staging System
Primary tumor (T)
Tx Primary tumor not assessable
T0 No evidence of primary tumor
T1 Tumor involving the ipsilateral parietal pleura (including mediastinal and diaphragmatic pleura) with or without involvement of visceral 
pleura
T2 Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic and visceral pleura) with at least one of the 
following features:
 Involvement of diaphragmatic muscle
 Extension of tumor from visceral pleura into the underlying lung parenchyma
T3 Locally advanced but potentially resectable tumor. Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphrag-
matic and visceral pleura) with at least one of the following features:
 Involvement of the endothoracic fascia
 Extension into the mediastinal fat
 Solitary, completely resectable focus invading soft tissues of the chest wall
 Non-transmural involvement of the pericardium
T4 Tumor involving all of the ipsilateral pleural surfaces with at least one of the following features:
 Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction
 Direct transdiaphragmatic extension of tumor to the peritoneum
 Direct extension of tumor to mediastinal organs
 Direct extension of tumor to the contralateral pleura
 Direct extension of tumor into the spine
 Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion, or tumor involving the myo-
cardium
Regional lymph nodes (N)
Nx Regional lymph nodes not assessable
N0 No regional lymph node metastases
N1 Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal lymph nodes (including the internal mammary, peridiaphragmatic, 
pericardial fat pad, or intercostal lymph nodes)
N2 Metastases in the contralateral bronchopulmonary, hilar, or mediastinal lymph nodes or ipsilateral or contralateral supraclavicular lymph 
nodes
Distant metastasis (M)
Mx Presence of distant metastases not assessable
M0 No evidence of distant metastases
M1 Evidence of distant metastases
Table 2  TNM Stage grouping 
according to the 8th edition of 
MPM Staging System
Stage N0 N1 N2
T1 IA II IIIB
T2 IB II IIIB
T3 IB IIIA IIIB
T4 IIIB IIIB IIIB
M1 IV IV IV
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(MRI) may be considered to define T stage. Imaging tests 
are crucial to guide the optimal biopsy site and to determine 
clinical staging according to the 8th Edition of AJCC/UICC 
TNM staging system (Tables  1 and 2). EBUS has higher 
sensitivity and negative predictive value than mediastinos-
copy when assessing nodal invasion in MPM [6].
Diagnostic method in pleural mesothelioma
Recommendation
The diagnosis of MPM should always be based on the 
results obtained from an adequate biopsy in the context 
of appropriate clinical, radiologic, and surgical findings 
[IIA]. In patients with undiagnosed pleural effusion in 
whom the differential diagnosis includes MPM, a thora-
coscopic biopsy should be considered. Alternative and less 
invasive methods, as image-guided needle biopsies, can 
be used in unfit patients not suitable for a thoracoscopy.
Literature review Ultrasound-guided thoracocentesis is 
recommended in patients with pleural effusion. Cytological 
assessment of pleural fluid has limited sensitivity for MPM 
diagnosis [7]. Biopsies can be obtained percutaneously 
under radiological guidance, under direct vision at thora-
coscopy (either by local anaesthetic thoracoscopy or video-
assisted thoracoscopic surgery [VATS]) or under open 
pleural biopsy. The biopsy technique will vary depending 
on the distribution of the disease, the presence of pleural 
effusion, the suitability for surgery or invasive procedures 
and their availability. A less invasive alternative for patients 
with pleural mass, nodular thickening, or unfit for surgery 
is performing a CT or ultrasound (US) guided core biopsy.
Methods to assess radiological response in pleural 
mesothelioma
Recommendation
Modified Response Evaluation Criteria in Solid Tumors 
(mRECIST) criteria version 1.1 is recommended when 
assessing tumor lesions and tumor response in CT scans 
and requires the expertise of a radiologist [IIA].
Literature review Response assessment in MPM using 
conventional RECIST is challenging due to its growth pat-
tern and morphology. In 2004, mRECIST were proposed to 
assess tumor response in MPM [8] which have been recently 
updated to version 1.1. Currently, mRECIST are considered 
the preferred method for tumor measurement, despite they 
have not been prospectively validated [9].
Local therapy
Surgery
The role of surgery in patients with MPM remains contro-
versial, mainly due to limited data available and the lack 
of standardization to define the best surgical approach, but 
above all, because surgery has not proven a robust survival 
benefit in randomized clinical trials. However, surgical 
resection may be appropriate on carefully evaluated patients 
in centers with experience in managing MPM.
Recommendation
1. For MPM patients with symptomatic pleural effusions 
candidates to palliative chemotherapy, complete drain-
age of the pleural space with subsequent pleurodesis is 
recommended.
(a) VATS-PP (partial removal of parietal and/or vis-
ceral pleura for diagnostic or palliative purposes) 
for the management of symptomatic MPM effu-
sions has no effect on overall survival and results 
in increased complications and longer hospital 
stay than talc pleurodesis [IA].
(b) In patients with lung entrapment, insertion of a 
tunneled pleural catheter can alleviate respiratory 
symptoms effectively, although might increase the 
risk of seeding along the catheter tract.
2. Surgical interventions for maximal cytoreduction with 
macroscopic complete resection of all tumor (defined 
as < 1 cm of residual tumor after resection and curative 
intents) include extrapleural pneumonectomy (EPP) 
and pleurectomy/decortication (P/D)  and should be 
performed in highly specialized centers by experienced 
thoracic surgeons. They should only be considered in 
selected patients with early stage (confined to pleural 
envelope, no N2 lymph node involvement) and epithe-
lioid histology, given the substantial morbidity and mor-
tality associated with these procedures.
(a) EPP involving extrapleural pneumonectomy, en 
bloc resection of parietal pleura, pericardium dia-
phragm, lung and visceral pleural treatment.
(b) EPD with extended pleurectomy/decortication 
with parietal and visceral pleurectomy, with 
resection of the diaphragm, and/or pericardium as 
required may result in lower perioperative mortal-
ity than EPP. EPD is the preferred surgical method 
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since has lower respiratory postoperative morbid-
ity and preserves better quality of life. This tech-
nique yielded longer overall survival compared 
with chemotherapy alone in some series.
Literature review Although initial studies suggested that 
VATS-PP might be superior option to talc pleurodesis, the 
MesoVATS randomized controlled trial demonstrated no 
survival advantage with VATS-PP in patients with pleural 
effusion, which increased length of hospital stay compared 
with talc pleurodesis [10]. To date, only one prospective, 
randomized trial, the Mesothelioma and Radical Surgery 
(MARS) trial, has evaluated the added benefit of perform-
ing EPP versus no EPP in the setting of trimodal therapy. 
No survival benefit was observed, with a median OS of 
14.4 months for the EPP group and 19.5 months for the no 
EPP group, (HR 2.75, p = 0.016) and 19% postoperative 
mortality rate observed in the EPP group [11]. However, 
these results are controversial due to the small sample size 
and the fact that OS was not the primary endpoint. Several 
metanalysis favored EPD over EPP because of the higher 
mortality after EPP without a survival benefit over EPD [12, 
13]. An ongoing randomized clinical trial (MARS 2) should 
determine whether P/D or EPD after induction chemother-
apy leads to superior outcomes compared with chemother-
apy alone.
Radiotherapy
Although mesothelioma cells are moderately sensitive to RT, 
its utilization is limited by high risk of injury in the lungs 
and other surrounding organs at risk and because did not 
improve overall survival.
Recommendation
1. Prophylactic RT of chest wall procedure tracts should 
not be routinely offered [IA].
2. The role of RT as part or multimodality treatment is 
controversial and due to intensive toxicity should be 
performed in highly specialized centers by experienced 
radiation oncologists. The best timing for delivering RT 
after surgical intervention and/ or in conjunction with 
chemotherapy should be discussed in a multidisciplinary 
team.
(a) Postoperative RT (45–60 Gy) after chemother-
apy and EPP reduce local recurrence but did not 
improve overall survival. Intensity-modulated 
radiation (IMRT) therapy seemed particularly 
promising and can reduce local recurrence after 
EPP and protect organs at risk. Postoperative RT 
after P/D is usually not recommended because of 
toxicity. Hemithoracic IMRT after P/D may be 
considered in centers with experience.
(b) Preoperative RT has not been shown to improve 
survival and may be considered in a context of 
clinical trials due to the high risk of severe post-
radiation neumonitis. IMRT neoadjuvant therapy 
followed by EPP may be an option for resectable 
epithelial MPM.
(c) Radical RT to the entire hemithorax used in isola-
tion in the setting of an intact lung and unresect-
able disease has not been shown to improve sur-
vival and is associated with unacceptable toxicity.
(d) Palliative RT for localized pain, dysphagia and 
airway obstruction in MPM can be considered. 
Although the optimal dose has not been estab-
lished, for patients with chest pain, doses ranging 
20–40 Gy appear to be effective.
Literature review Several randomized clinical trials 
(RCT) have not shown a reduction in tract metastases with 
prophylactic RT to chest wall procedure tracts, and did 
not improve quality of life, chest pain, analgesia require-
ment and survival [14, 15]. The efficacy of EPP followed 
by hemithoracic RT has been promising, with in-field 
failure rates of approximately 15–30%. However, in the 
SAKK17/04 trial, comparing adjuvant hemithoracic radi-
ation vs no RT in EPP resected patients, no significant 
differences in terms of overall survival were observed. 
This trial has several important limitations: early close 
due to poor accrual and substantial patient dropout from 
registration to randomization. The use of EPP has gradu-
ally declined in recent years in favor of using less radi-
cal lung-sparing approaches such as P/D. The hemitho-
racic intensity-modulated pleural radiation technique 
(IMPRINT) in conjunction with chemotherapy and P/D 
demonstrated that a planned does of 50.4 Gy in 23 frac-
tions can be administered safely [16]. Neoadjuvant IMRT 
followed by EPP has been evaluated in the SMART trial, 
with a median OS of 51 months and disease-free survival 
of 47 months in patients with epithelial subtype compared 
with 10 and 8 months, respectively, for biphasic subtypes 
[17].
Indications for palliative RT in patients with MPM 
include pain management, treatment of dysphagia and 
airway obstruction, and relief of compression of the supe-
rior vena cava. RT has also been used to palliate distant 
metastases, such as those in the bone and the brain. The 
optimal radiotherapy dose remains unclear; a phase II trial, 
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the SYSTEMS2, is aiming to establish optimal dose/frac-




Following multidisciplinary assessment in the thoracic 
tumors board, patients with MPM who are not suitable 
for surgery should receive first-line treatment with plat-
inum-based chemotherapy [IA]. In patients who cannot 
tolerate cisplatin, carboplatin might be used in combina-
tion with pemetrexed [IIA]. Maintenance with pemetrexed 
does not improve overall survival [IIA]. The standard of 
care consists of 4–6 cycles of cisplatin plus pemetrexed. 
Chemotherapy should not be postponed and should be con-
sidered before clinical deterioration. Clinical trials should 
be always considered.
Literature review In the EMPHACIS trial, MPM patients 
not suitable for curative surgery were randomized to cis-
platin plus pemetrexed versus cisplatin alone [18]. Com-
bining cisplatin plus pemetrexed improved the response 
rate (41.3% vs 16.7%), PFS (5.7 vs 3.9 months, p = 0.001), 
overall survival (12.1 vs 9.3 months, HR = 0.77, p = 0.02) 
and patients’ quality of life. Similar efficacy results were 
achieved with carboplatin in non-randomized phase II tri-
als [19]. The MAPS trial evaluated the addition of beva-
cizumab to standard chemotherapy followed by mainte-
nance with bevacizumab improved overall survival (18.8 
vs 16.1 months, HR = 0.77) at the expense of higher tox-
icity [20]. In the STELLAR trial, a randomized phase II 
trial, TTFields were delivered to the thorax in addition 
to conventional chemotherapy in patients with unresect-
able MPM [21]. Median overall survival was 18.2 months 
and hematological toxicity constituted the most common 
grade 3 adverse events. Bevacizumab and TTFields has 
not been approved by the European Medicines Agency.
Second‑line therapy
Recommendation
Participation in clinical trials should be encouraged due 
to the limited efficacy of second-line chemotherapy. 
Retreatment with pemetrexed-based chemotherapy can be 
considered in MPM patients who achieved durable dis-
ease control (> 6 months) with first-line pemetrexed-based 
chemotherapy [IIB]. Second-line pemetrexed is recom-
mended in patients previously treated with first-line chem-
otherapy regimens that did not include pemetrexed [IA]. 
Second-line chemotherapy with gemcitabine or vinorelbine 
can be offered [IIB].
Literature review No therapy has demonstrated to increase 
overall survival compared to supportive care alone in rand-
omized clinical trials. The limited efficacy of drugs evalu-
ated in second line warrants patients’ referral for partici-
pating in clinical trials. Vinorelbine and gemcitabine are 
used as a second-line treatment in MPM, despite its modest 
efficacy reported in single arm phase II clinical trials. Dis-
tinct immune checkpoint inhibitors have been evaluated in 
single arm phase II clinical trials with promising efficacy, 
ie, combination for nivolumab plus ipilimumab (MAPS2) 
or nivolumab alone  (INITIATE, MERIT). However, the 
PROMISE-meso phase III randomized clinical trial did not 
demonstrate survival benefit of pembrolizumab over phy-
sician-choice chemotherapy (gemcitabine or vinorelbine) 
[22].
Future directions
The recent advances in understanding the biology of meso-
thelioma and the identification of novel potential targets may 
open new therapeutic avenues.
Preclinical data showed that BAP1 inactivation sensitizes 
mesothelial cells to inhibition of enhancer of zeste-homolog 
2 (EZH2). Tazemetostat, an EZH2 inhibitor, showed promis-
ing results in a phase II trial for patients with relapsed MPM.
The most promising results come from clinical trials 
assessing the combination of immunotherapy with other 
treatments such as dual immune checkpoint inhibition, 
Chimeric Antigen Receptor Transduced T cells (CAR-T) 
or chemotherapy. A phase I trial combining CAR-T cells 
given intrapleurally and pembrolizumab achieved an over-
all response rate of 50% in 14 patients with MPM. Further 
validation of this approach is warranted.
The combination of platinum and pemetrexed with 
durvalumab in previously untreated patients with MPM 
has shown promising overall survival (median ranging 
18.4–21.1 months) and acceptable safety profile in the 
DREAM and PrECOG LLC studies [20]. Ongoing phase 
III clinical trials are evaluating chemotherapy combined 
with immune checkpoint inhibitors and antiangiogenic 
therapies. Using a distinct approach, the phase III clinical 
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trial CheckMate-743 compared frontline nivolumab plus 
ipilimumab with platinum plus pemetrexed in previously 
untreated MPM, has recently demonstrated significant 
improvement in overall survival with the dual combina-
tion of immune checkpoint inhibitors (18.1 vs 14.1 months, 
HR = 0.74, p = 0.002) [24]. Patients with PD-L1 positive or 
non-epithelioid histology had larger benefit (HR = 0.69 and 
0.46, respectively).
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